GrowBLOX Sciences, a biopharmaceutical company with
state-of-the-art technologies in plant biology and cultivation designed to
produce consistent medicinal cannabis, today announced that over the course of
the next few weeks it will implement certain changes in management personnel
and operating procedures in preparation for the commencement of cultivation
operations through its majority-owned subsidiary, GB Sciences Nevada, LLC.
“The build out of our principal cultivation facility in
Nevada is proceeding well and on schedule. As we transition from our
engineering intensive development stage, involving largely R&D and
licensure efforts, to the day-to-day operations of producing an excellent
product, branding it appropriately, and maximizing our revenue, we will need to
significantly beef up our staff,” CEO Craig Ellins stated in the news release.
“We have brought in John Poss as a consultant to put in effect some of these
changes. We feel that John will be instrumental in helping us to achieve that
transition smoothly and expeditiously.”
John Poss, a former CPA, is a senior executive with a track
record of improving performance in technology, logistics, operations, business
systems and finance. His experience includes CEO, COO, CFO and CTO of both
public and private companies with sales ranging from $10 million to $450
million as well as over 15 years of consulting experience. He also has
extensive M&A experience, both buy and sell side, including private equity.
He also holds two United States patents.
The company also plans to appoint a general manager for the
GBS Nevada Venture in the near future, as well as support staff for the
30,000-square-foot cultivation facility. Key personnel for the retail location
in Las Vegas as well as the delivery service will also be put in place in the
upcoming weeks. Product development and scientific validation of consumer
facing products will be managed by a combination of in-house scientists and
contracted chemists and formulators.
“Our drug discovery strategy and clinical research will be
enhanced by the success of our Nevada operations. Profiling proprietary strains
for their therapeutic properties is essential for the scientific and medical
evolution of cannabis. Our competitive advantage lies in the privilege to legally
grow and scientifically study medical cannabis here in Nevada. It is extremely
important to our shareholders that we have the ability to test and develop
products on a commercial scale but with laboratory precision,” said Chief
Science Officer Dr. Andrea Small-Howard.
In conjunction with the aforementioned changes, GBLX has
replaced its PCAOB auditor with Patrick Heyn, CPA, who was the concurring
auditor for the company’s most recent audited statement. GBLX expects to
shortly announce further additions of key personnel to manage the
revenue-producing operations expected to begin in the early fourth quarter of
2015.
For more information, visit www.growblox.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment